| Assay ID | Title | Year | Journal | Article |
|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1393270 | Half life in Wistar rat at 10 mg/kg, po or 1 mg/kg, iv | 2018 | Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
| Chemical Approaches to Modulating Complement-Mediated Diseases. |
| AID1506676 | Antagonist activity at of C5aR in in human macrophages assessed as half life of residence time for maintaining reduction in C5a-induced macrophage response | | | |
| AID1393271 | Antagonist activity at C5aR1 in human neutrophils assessed as inhibition of 0.1 nM recombinant human C5a-induced intracellular calcium release | 2018 | Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
| Chemical Approaches to Modulating Complement-Mediated Diseases. |
| AID1393269 | Oral bioavailability in Wistar rat at 10 mg/kg | 2018 | Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
| Chemical Approaches to Modulating Complement-Mediated Diseases. |
| AID1393268 | Antagonist activity at C5aR1 in HMDM assessed as inhibition of 1 nM recombinant human C5a-induced intracellular calcium release preincubated for 1 hr followed by human C5a-induction and measured after 60 hrs by FLIPR assay | 2018 | Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
| Chemical Approaches to Modulating Complement-Mediated Diseases. |
| AID1347000 | Human C5a1 receptor (Complement peptide receptors) | 2002 | The Journal of biological chemistry, Dec-20, Volume: 277, Issue:51
| Identification of a potent and orally active non-peptide C5a receptor antagonist. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |